|
1
|
Raza A and Sood GK: Hepatocellular
carcinoma review: Current treatment and evidence-based medicine.
World J Gastroenterol. 20:4115–4127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bruix J and Sherman M: American
Association for the Study of Liver Diseases: Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
European Association For The Study Of The
Liver; European Organisation For Research And Treatment Of Cancer,
. EASL-EORTC clinical practice guidelines: Management of
hepatocellular carcinoma. J Hepatol. 56:908–943. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Forner A, Llovet JM and Bruix J:
Hepatocellular carcinoma. Lancet. 379:1245–1255. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwartz JD, Schwartz M, Mandeli J and
Sung M: Neoadjuvant and adjuvant therapy for resectable
hepatocellular carcinoma: Review of the randomised clinical trials.
Lancet Oncol. 3:593–603. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lai EC, Lo CM, Fan ST, Liu CL and Wong J:
Postoperative adjuvant chemotherapy after curative resection of
hepatocellular carcinoma: A randomized controlled trial. Arch Surg.
133:183–188. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Izumi R, Shimizu K, Iyobe T, Ii T, Yagi M,
Matsui O, Nonomura A and Miyazaki I: Postoperative adjuvant hepatic
arterial infusion of Lipiodol containing anticancer drugs in
patients with hepatocellular carcinoma. Hepatology. 20:295–301.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Miyake Y, Takaki A, Iwasaki Y and Yamamoto
K: Meta-analysis: Interferon-alpha prevents the recurrence after
curative treatment of hepatitis C virus-related hepatocellular
carcinoma. J Viral Hepat. 17:287–292. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lo CM, Liu CL, Chan SC, Lam CM, Poon RT,
Ng IO, Fan ST and Wong J: A randomized, controlled trial of
postoperative adjuvant interferon therapy after resection of
hepatocellular carcinoma. Ann Surg. 245:831–842. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shen YC, Hsu C, Chen LT, Cheng CC, Hu FC
and Cheng AL: Adjuvant interferon therapy after curative therapy
for hepatocellular carcinoma (HCC): A meta-regression approach. J
Hepatol. 52:889–894. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhong Y, Liu B, Deng M and Xu R: Adjuvant
systemic drug therapy and recurrence of hepatocellular carcinoma
following curative resection. Drug Discov Ther. 7:164–166.
2013.PubMed/NCBI
|
|
13
|
Minagawa M and Makuuchi M: Treatment of
hepatocellular carcinoma accompanied by portal vein tumor thrombus.
World J Gastroenterol. 12:7561–7567. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Takizawa D, Kakizaki S, Sohara N, Sato K,
Takagi H, Arai H, Katakai K, Kojima A, Matsuzaki Y and Mori M:
Hepatocellular carcinoma with portal vein tumor thrombosis:
Clinical characteristics, prognosis and patient survival analysis.
Dig Dis Sci. 52:3290–3295. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Okuda K, Ohtsuki T, Obata H, Tomimatsu M,
Okazaki N, Hasegawa H, Nakajima Y and Ohnishi K: Natural history of
hepatocellular carcinoma and prognosis in relation to treatment.
Study of 850 patients. Cancer. 56:918–928. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST
and Wong J: Natural history of untreated nonsurgical hepatocellular
carcinoma. Am J Gastroenterol. 100:1995–2004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee HS, Kim JS, Choi IJ, Chung JW, Park JH
and Kim CY: The safety and efficacy of transcatheter arterial
chemoembolization in the treatment of patients with hepatocellular
carcinoma and main portal vein obstruction. A prospective
controlled study. Cancer. 79:2087–2094. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chuan-Xing L, Xu H, BaoShan H, Yong L,
PeiJian S, XianYi Y, XiaoNing L and Li-Gong L: Efficacy of therapy
for hepatocellular carcinoma with portal vein tumor thrombus:
Chemoembolization and stent combined with iodine-125 seed. Cancer
Biol Ther. 12:865–871. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43–9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilhelm S, Carter C, Lynch M, Lowinger T,
Dumas J, Smith RA, Schwartz B, Simantov R and Kelley S: Discovery
and development of sorafenib: A multikinase inhibitor for treating
cancer. Nat Rev Drug Discov. 5:835–844. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang YS, Adnane J, Trail PA, Levy J,
Henderson A, Xue D, Bortolon E, Ichetovkin M, Chen C, McNabola A,
et al: Sorafenib (BAY 43–9006) inhibits tumor growth and
vascularization and induces tumor apoptosis and hypoxia in RCC
xenograft models. Cancer Chemother Pharmacol. 59:561–574. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard
P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A,
et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J
Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang SN, Chuang SC and Lee KT: Efficacy of
sorafenib as adjuvant therapy to prevent early recurrence of
hepatocellular carcinoma after curative surgery: A pilot study.
Hepatol Res. 44:523–531. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bruix J, Sherman M, Llovet JM, Beaugrand
M, Lencioni R, Burroughs AK, Christensen E, Pagliaro L, Colombo M
and Rodés J: EASL Panel of Experts on HCC: Clinical management of
hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL
conference. European Association for the Study of the Liver. J
Hepatol. 35:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Salerno F, Merli M, Cazzaniga M, Valeriano
V, Rossi P, Lovaria A, Meregaglia D, Nicolini A, Lubatti L and
Riggio O: MELD score is better than Child-Pugh score in predicting
3-month survival of patients undergoing transjugular intrahepatic
portosystemic shunt. J Hepatol. 36:494–500. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kleihues P and Sobin LH: World Health
Organization classification of tumors. Cancer. 88:28872000.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wanless IR: International Working Party:
Terminology of nodular hepatocellular lesions. Hepatology.
22:983–993. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sobin LH and Fleming ID: TNM
Classification of Malignant Tumors, fifth edition (1997). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ,
Chen MS and Shi M: Hepatic resection versus transarterial lipiodol
chemoembolization as the initial treatment for large, multiple and
resectable hepatocellular carcinomas: A prospective nonrandomized
analysis. Radiology. 259:286–295. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Therasse P, Arbuck SG, Eisenhauer EA,
Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van
Oosterom AT, Christian MC and Gwyther SG: New guidelines to
evaluate the response to treatment in solid tumors. European
Organization for Research and Treatment of Cancer, National Cancer
Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Imamura H, Matsuyama Y, Tanaka E, Ohkubo
T, Hasegawa K, Miyagawa S, Sugawara Y, Minagawa M, Takayama T,
Kawasaki S and Makuuchi M: Risk factors contributing to early and
late phase intrahepatic recurrence of hepatocellular carcinoma
after hepatectomy. J Hepatol. 38:200–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wu CY, Chen YJ, Ho HJ, Hsu YC, Kuo KN, Wu
MS and Lin JT: Association between nucleoside analogues and risk of
hepatitis B virus-related hepatocellular carcinoma recurrence
following liver resection. JAMA. 308:1906–1914. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhong JH, Ke Y, Gong WF, Xiang BD, Ma L,
Ye XP, Peng T, Xie GS and Li LQ: Hepatic resection associated with
good survival for selected patients with intermediate and
advanced-stage hepatocellular carcinoma. Ann Surg. 260:329–340.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shindoh J, Hasegawa K, Inoue Y, Ishizawa
T, Nagata R, Aoki T, Sakamoto Y, Sugawara Y, Makuuchi M and Kokudo
N: Risk factors of post-operative recurrence and adequate surgical
approach to improve long-term outcomes of hepatocellular carcinoma.
HPB (Oxford). 15:31–39. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tanaka K, Shimada M and Kudo M:
Characteristics of long-term survivors following sorafenib
treatment for advanced hepatocellular carcinoma: Report of a
workshop at the 50th annual meeting of the liver cancer study group
of Japan. Oncology. 87:(Suppl 1). 104–109. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nagano H, Miyamoto A, Wada H, Ota H,
Marubashi S, Takeda Y, Dono K, Umeshita K, Sakon M and Monden M:
Interferon-alpha and 5-fluorouracil combination therapy after
palliative hepatic resection in patients with advanced
hepatocellular carcinoma, portal venous tumor thrombus in the major
trunk and multiple nodules. Cancer. 110:2493–2501. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dollinger MM, Lautenschlaeger C, Lesske J,
Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R
and Fleig WE: AIO Hepatobiliary Study Group: Thymostimulin versus
placebo for palliative treatment of locally advanced or
metastasised hepatocellular carcinoma: A phase III clinical trial.
BMC Cancer. 10:4572010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Shiozawa K, Watanabe M, Ikehara T,
Matsukiyo Y, Kogame M, Kanayama M, Matsui T, Kikuchi Y, Ishii K,
Igarashi Y and Sumino Y: Sustained complete response of
hepatocellular carcinoma with portal vein tumor thrombus following
discontinuation of sorafenib: A case report. Oncol Lett. 7:50–52.
2014.PubMed/NCBI
|
|
43
|
Wang Z, Zhou J, Fan J, Qiu SJ, Yu Y, Huang
XW and Tang ZY: Effect of rapamycin alone and in combination with
sorafenib in an orthotopic model of human hepatocellular carcinoma.
Clin Cancer Res. 14:5124–5130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Richly H, Schultheis B, Adamietz IA,
Kupsch P, Grubert M, Hilger RA, Ludwig M, Brendel E, Christensen O
and Strumberg D: Combination of sorafenib and doxorubicin in
patients with advanced hepatocellular carcinoma: Results from a
phase I extension trial. Eur J Cancer. 45:579–587. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Chung YH, Han G, Yoon JH, Yang J, Wang J,
Shao GL, Kim BI, Lee TY and Chao Y: Interim analysis of START:
Study in Asia of the combination of TACE (transcatheter arterial
chemoembolization) with sorafenib in patients with hepatocellular
carcinoma trial. Int J Cancer. 132:2448–2458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Barbier L, Muscari F, Le Guellec S,
Pariente A, Otal P and Suc B: Liver resection after downstaging
hepatocellular carcinoma with sorafenib. Int J Hepatol.
2011:7910132011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Azad NS, Posadas EM, Kwitkowski VE,
Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL,
Premkumar A, et al: Combination targeted therapy with sorafenib and
bevacizumab results in enhanced toxicity and antitumor activity. J
Clin Oncol. 26:3709–3714. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sposito C, Mariani L, Germini A, Reyes M
Flores, Bongini M, Grossi G, Bhoori S and Mazzaferro V: Comparative
efficacy of sorafenib versus best supportive care in recurrent
hepatocellular carcinoma after liver transplantation: A
case-control study. J Hepatol. 59:59–66. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Feng YX, Wang T, Deng YZ, Yang P, Li JJ,
Guan DX, Yao F, Zhu YQ, Qin Y, Wang H, et al: Sorafenib suppresses
postsurgical recurrence and metastasis of hepatocellular carcinoma
in an orthotopic mouse model. Hepatology. 53:483–492. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wang Z, Hu J, Qiu SJ, Huang XW, Dai Z, Tan
CJ, Zhou J and Fan J: An investigation of the effect of sorafenib
on tumor growth and recurrence after liver cancer resection in nude
mice independent of phosphorylated extracellular signal-regulated
kinase levels. Expert Opin Investig Drugs. 20:1039–1045. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Bruix J, Takayama T, Mazzaferro V, et al:
STORM: A phase III randomized, double-blind, placebo-controlled
trial of adjuvant sorafenib after resection or ablation to prevent
recurrence of hepatocellular carcinoma (HCC). J Clin Oncol.
32:(suppl 5): Abtract 4006. 2014.
|
|
52
|
Inghilesi AL, Gallori D, Antonuzzo L,
Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B,
Gianni E, et al: Predictors of survival in patients with
established cirrhosis and hepatocellular carcinoma treated with
sorafenib. World J Gastroenterol. 20:786–794. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wörns MA, Koch S, Niederle IM, Marquardt
JU, NguyenTat M, Gamstätter T, Schuchmann M, Schulze-Bergkamen H,
Galle PR and Weinmann A: The impact of patient and tumour baseline
characteristics on the overall survival of patients with advanced
hepatocellular carcinoma treated with sorafenib. Dig Liver Dis.
45:408–413. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ikeda M, Okusaka T, Furuse J, Mitsunaga S,
Ueno H, Yamaura H, Inaba Y, Takeuchi Y, Satake M and Arai Y: A
multi-institutional phase II trial of hepatic arterial infusion
chemotherapy with cisplatin for advanced hepatocellular carcinoma
with portal vein tumor thrombosis. Cancer Chemother Pharmacol.
72:463–470. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kalva SP, Pectasides M, Liu R, Rachamreddy
N, Surakanti S, Yeddula K, Ganguli S, Wicky S, Blaszkowsky LS and
Zhu AX: Safety and effectiveness of chemoembolization with
drug-eluting beads for advanced-stage hepatocellular carcinoma.
Cardiovasc Intervent Radiol. 37:381–387. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Fan J, Wu ZQ, Tang ZY, Zhou J, Qiu SJ, Ma
ZC, Zhou XD and Ye SL: Multimodality treatment in hepatocellular
carcinoma patients with tumor thrombi in portal vein. World J
Gastroenterol. 7:28–32. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tazawa J, Maeda M, Sakai Y, Yamane M,
Ohbayashi H, Kakinuma S, Miyasaka Y, Nagayama K, Enomoto N and Sato
C: Radiation therapy in combination with transcatheter arterial
chemoembolization for hepatocellular carcinoma with extensive
portal vein involvement. J Gastroenterol Hepatol. 16:660–665. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS
and Lau WY: Hepatic resection versus transcatheter arterial
chemoembolization for the treatment of hepatocellular carcinoma
with portal vein tumor thrombus. Cancer. 118:4725–4736. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Chen XP, Qiu FZ, Wu ZD, Zhang ZW, Huang
ZY, Chen YF and Zhang BX: Effects of location and extension of
portal vein tumor thrombus on long-term outcomes of surgical
treatment for hepatocellular carcinoma. Ann Surg Oncol. 13:940–946.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Le Treut YP, Hardwigsen J, Ananian P,
Saisse J, Gregoire E, Richa H and Campan P: Resection of
hepatocellular carcinoma with tumor thrombus in the major
vasculature. A European case-control series. J Gastrointest Surg.
10:855–862. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Shi J, Lai EC, Li N, Guo WX, Xue J, Lau
WY, Wu MC and Cheng SQ: Surgical treatment of hepatocellular
carcinoma with portal vein tumor thrombus. Ann Surg Oncol.
17:2073–2080. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Kim DY, Park W, Lim DH, Lee JH, Yoo BC,
Paik SW, Kho KC, Kim TH, Ahn YC and Huh SJ: Three-dimensional
conformal radiotherapy for portal vein thrombosis of hepatocellular
carcinoma. Cancer. 103:2419–2426. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zhang XB, Wang JH, Yan ZP, Qian S, Du SS
and Zeng ZC: Hepatocellular carcinoma with main portal vein tumor
thrombus: Treatment with 3-dimensional conformal radiotherapy after
portal vein stenting and transarterial chemoembolization. Cancer.
115:1245–1252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Berk V, Kaplan MA, Tonyali O, Buyukberber
S, Balakan O, Ozkan M, Demirci U, Ozturk T, Bilici A, Tastekin D,
et al: Efficiency and side effects of sorafenib therapy for
advanced hepatocellular carcinoma: A retrospective study by the
anatolian society of medical oncology. Asian Pac J Cancer Prev.
14:7367–7369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zugazagoitia J, Manzano A, Sastre J,
Ladero JM, Puente J and Díaz-Rubio E: Sorafenib for non-selected
patient population with advanced hepatocellular carcinoma: Efficacy
and safety data according to liver function. Clin Transl Oncol.
15:146–153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Pressiani T, Boni C, Rimassa L, Labianca
R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C,
Mucciarini C, et al: Sorafenib in patients with Child-Pugh class A
and B advanced hepatocellular carcinoma: A prospective feasibility
analysis. Ann Oncol. 24:406–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Palmer DH, Hussain SA, Smith AJ,
Hargreaves S, Ma YT, Hull D, Johnson PJ and Ross PJ: Sorafenib for
advanced hepatocellular carcinoma (HCC): Impact of rationing in the
United Kingdom. Br J Cancer. 109:888–890. 2013. View Article : Google Scholar : PubMed/NCBI
|
